Orderly leadership transition removes near-term governance overhang. Monitor the next quarterly earnings (due August) for any strategic shifts under new CEO or changes in coach-led model performance. The share plan increase is standard and unlikely to materially dilute.
Price Chart
Executive Summary
Medifast filed an 8-K reporting stockholder approval of an amended share incentive plan and the formal appointment of Nicholas Johnson as CEO, effective June 1, 2026, succeeding Dan Chard who stays as non-executive Chairman. The plan adds 250,000 shares for equity awards, and Johnson's compensation includes a $600,000 base salary, 100% target bonus, and 250% LTI target. The transition was pre-announced in January and is orderly.
Key Facts
- Stockholders approved Amended and Restated 2012 Share Incentive Plan, increasing authorized shares by 250,000 to approximately 1,425,000 shares.
- Nicholas Johnson appointed CEO effective June 1, 2026; Dan Chard transitions to non-executive Chairman.
- Johnson's compensation: $600,000 base salary, 100% target bonus, 250% LTI target (69% total comp increase).
- All seven director nominees were elected; RSM US LLP ratified as auditor; say-on-pay and share plan approved.
- CEO transition was disclosed in a prior 8-K on January 5, 2026; departure not due to disagreements.
Financial Impact
None directly. The share plan increase enables future equity grants but the number (250K shares) is modest relative to market cap (~$140M). CEO compensation increase is routine for promotion.
Risk Factors
- Potential future dilution from equity grants under the new share plan.
- Execution risk under new CEO in a highly competitive metabolic health market.
- Bearish analyst consensus (0% buy, 8 sell/strong sell) suggests low market confidence in near-term fundamentals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-038109 |
| Document: med-20260519.htm | 0001628280-26-038109 |
| Document: pressrelease-nickjohnsonceo.htm | 0001628280-26-038109 |
| Document: nickjohnson_promotionlette.htm | 0001628280-26-038109 |
| Document: 0001628280-26-038109-index-headers.html | 0001628280-26-038109 |
| Document: 0001628280-26-038109-index.html | 0001628280-26-038109 |
| Document: 0001628280-26-038109.txt | 0001628280-26-038109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $11.56 | awaiting T+5 | — | $12.59 (+8.91%) |
Oct 15, 2026 12d ago | Press Release | $12.06 $12.17 | ▲ +0.91% | ▲ +1.93% | $12.59 (+4.39%) |
Oct 6, 2026 21d ago | Press Release | $11.51 $11.67 | ▲ +1.39% | ▲ +1.53% | $12.59 (+9.38%) |
Oct 1, 2026 26d ago | Press Release | $11.43 $11.43 | · 0.00% | ▼ −1.30% | $12.59 (+10.15%) |
Aug 28, 2026 8w ago | Insider Buy | $12.18 $12.63 | ▲ +3.69% | ▲ +3.59% | $12.59 (+3.37%) |
Aug 26, 2026 8w ago | Insider Buy | $12.22 $12.67 | ▲ +3.68% | ▲ +3.80% | $12.59 (+3.03%) |
Aug 21, 2026 9w ago | Insider Buy | $11.95 $12.18 | ▲ +1.92% | ▲ +1.45% | $12.59 (+5.36%) |
Jul 17, 2026 14w ago | 8-K | $10.26 $9.45 | ▼ −7.89% | ▼ −7.21% | $12.59 (+22.71%) |
Jun 1, 2026 21w ago | 8-K | $12.70 $12.10 | ▼ −4.72% | ▼ −1.97% | $12.59 (−0.87%) |
May 26, 2026 21w ago | 8-K | $12.72 $12.36 | ▼ −2.83% | ▼ −4.04% | $12.59 (−1.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers